Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.vaccine.2009.07.098
DC Field | Value | |
---|---|---|
dc.title | Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study | |
dc.contributor.author | Phua, K.B. | |
dc.contributor.author | Lim, F.S. | |
dc.contributor.author | Teoh, Y.L. | |
dc.contributor.author | Lau, Y.L. | |
dc.contributor.author | Nelson, E.A.S. | |
dc.contributor.author | Huang, L.M. | |
dc.contributor.author | Quak, S.H. | |
dc.contributor.author | Lee, B.W. | |
dc.contributor.author | Tang, H. | |
dc.contributor.author | Boudville, I. | |
dc.contributor.author | Oostvogels, L.C. | |
dc.contributor.author | Suryakiran, P.V. | |
dc.contributor.author | Smolenov, I.V. | |
dc.contributor.author | Han, H.H. | |
dc.contributor.author | Bock, H.L. | |
dc.date.accessioned | 2011-08-16T07:43:27Z | |
dc.date.available | 2011-08-16T07:43:27Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Phua, K.B., Lim, F.S., Teoh, Y.L., Lau, Y.L., Nelson, E.A.S., Huang, L.M., Quak, S.H., Lee, B.W., Tang, H., Boudville, I., Oostvogels, L.C., Suryakiran, P.V., Smolenov, I.V., Han, H.H., Bock, H.L. (2009). Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study. Vaccine 27 (43) : 5936-5941. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2009.07.098 | |
dc.identifier.issn | 0264410X | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/25701 | |
dc.description.abstract | This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N = 5359) or placebo (N = 5349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild-type G1P[8] and 93.6% (95%CI:74.7%; 99.3%) against circulating non-G1 rotavirus types. No intussusception cases were reported within 31 days post-vaccination. RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population. © 2009 Elsevier Ltd. All rights reserved. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.vaccine.2009.07.098 | |
dc.source | Scopus | |
dc.subject | Diarrhoea | |
dc.subject | Efficacy | |
dc.subject | Gastroenteritis | |
dc.subject | Human rotavirus vaccine | |
dc.subject | Rotavirus | |
dc.type | Article | |
dc.contributor.department | PAEDIATRICS | |
dc.description.doi | 10.1016/j.vaccine.2009.07.098 | |
dc.description.sourcetitle | Vaccine | |
dc.description.volume | 27 | |
dc.description.issue | 43 | |
dc.description.page | 5936-5941 | |
dc.identifier.isiut | 000271170500004 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.